All In Biotech

Drug Trial Radar · NCT07942584

Intravenous Recombinant Human Prourokinase (rhPro-UK) for Acute Ischemic Stroke Within 4.5 to 24 Hours of Onset

A Multicenter, Randomized, Double-Blind, Double-Dummy, Standard-of-Care-Controlled Phase III Clinical Trial of Intravenous Recombinant Human Prourokinase (rhPro-UK) for the Treatment of Acute Ischemic Stroke Within 4.5 to 24 Hours of Symptom Onset

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 978 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

978

Planned (sponsor's estimate)

Start

Nov 30, 2026

Primary completion

Mar 1, 2029

Study completion Jun 1, 2029

Sponsor

Sponsor type
Industry
First posted
Nov 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, double-dummy, standard-of-care-controlled Phase III clinical trial to evaluate the efficacy and safety of intravenous recombinant human prourokinase (rhPro-UK) in adult patients with acute ischemic stroke (AIS) within 4.5 to 24 hours of symptom onset, including wake-up stroke and unwitnessed stroke.Eligible patients with salvageable ischemic tissue confirmed by CT perfusion or MRI perfusion/diffusion imaging will be randomized in a 1:1 ratio to receive either intravenous rhPro-UK 35 mg plus oral aspirin enteric-coated tablet placebo, or intravenous rhPro-UK placebo plus oral aspirin enteric-coated tablets 100-300 mg (standard of care).The primary objective is to evaluate the efficacy of intravenous rhPro-UK compared with standard of care in achieving a favorable functional outcome, defined as a modified Rankin Scale (mRS) score of 0-1 at 90 days after treatment. A total of 978 participants (489 per arm) will be enrolled at multiple centers in China.

Conditions

  • Acute Ischemic Stroke AIS

Interventions

  • Recombinant Human Prourokinase for Injection (rhPro-UK)Drug

    rhPro-UK 35 mg dissolved in normal saline, administered intravenously as a single dose: 15 mg slow intravenous bolus over 3 minutes, followed by 20 mg intravenous infusion/pump over 30 minutes. Treatment initiation must be \>4.5 hours and \<=24 hours after stroke onset.

  • Aspirin Enteric-Coated TabletsDrug

    Oral aspirin enteric-coated tablets 100-300 mg, administered once at the start of thrombolysis (dose at the investigator's discretion). Subsequent clinical antiplatelet therapy is initiated no earlier than 24 hours after completion of the investigational product administration.

  • Aspirin Enteric-Coated Tablet PlaceboDrug

    Oral placebo matching aspirin enteric-coated tablets, 100-300 mg, administered once at the start of thrombolysis (dose at the investigator's discretion).

  • rhPro-UK PlaceboDrug

    Placebo matching rhPro-UK for injection, dissolved in normal saline and administered intravenously with the same regimen as rhPro-UK (15 mg-equivalent slow intravenous bolus over 3 minutes, followed by 20 mg-equivalent intravenous infusion/pump over 30 minutes), single dose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Participants Achieving a Favorable Functional Outcome (mRS 0-1)Time frame: 90 days after treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Tiantan Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.